Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund
August 26, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, New Jersey, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (the “Company” or “Nuvectis”), a biopharmaceutical company focused on the development of innovative precision medicines...